Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:OREX
- CUSIP: 68616410
- Web: www.orexigen.com
Capitalization:- Market Cap: $32.71 million
- Outstanding Shares: 15,431,000
Average Prices:- 50 Day Moving Avg: $2.35
- 200 Day Moving Avg: $2.95
- 52 Week Range: $1.65 - $5.70
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.38
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $63.39 million
- Price / Sales: 0.52
- Book Value: ($2.76) per share
- Price / Book: -0.77
Profitability:- EBIDTA: ($163,640,000.00)
- Net Margins: -120.77%
- Return on Equity: -824.15%
- Return on Assets: -61.12%
Debt:- Debt-to-Equity Ratio: -4.08%
- Current Ratio: 2.74%
- Quick Ratio: 2.36%
Misc:- Average Volume: 70,539 shs.
- Beta: 2.45
- Short Ratio: 30.24
Frequently Asked Questions for Orexigen Therapeutics (NASDAQ:OREX)
What is Orexigen Therapeutics' stock symbol?
Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."
How were Orexigen Therapeutics' earnings last quarter?
Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.82) EPS for the quarter, topping the Zacks' consensus estimate of ($2.40) by $0.58. The firm earned $23.36 million during the quarter, compared to the consensus estimate of $20 million. Orexigen Therapeutics had a negative return on equity of 824.15% and a negative net margin of 120.77%. The firm's revenue was up 199.9% on a year-over-year basis. During the same period in the prior year, the business earned ($1.73) EPS. View Orexigen Therapeutics' Earnings History.
When will Orexigen Therapeutics make its next earnings announcement?
Who are some of Orexigen Therapeutics' key competitors?
Some companies that are related to Orexigen Therapeutics include Motif Bio PLC (MTFB), TRACON Pharmaceuticals (TCON), Flex Pharma (FLKS), Endocyte (ECYT), Microbot Medical (MBOT), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), Leap Therapeutics (LPTX), Xenon Pharmaceuticals (XENE), OptiBiotix Health PLC (OPTI), Capricor Therapeutics (CAPR), Avacta Group Plc (AVCT), pSivida Corp. (PSDV), Proteostasis Therapeutics (PTI), Actinium Pharmaceuticals (ATNM), Nivalis Therapeutics (ALPN), Inotek Pharmaceuticals Corporation (ITEK) and Ampio Pharmaceuticals (AMPE).
Who are Orexigen Therapeutics' key executives?
Orexigen Therapeutics' management team includes the folowing people:
- Patrick J. Mahaffy, Independent Chairman of the Board
- Michael A. Narachi, President, Chief Executive Officer, Director
- Jason A. Keyes, Chief Financial Officer, Senior Vice President
- Thomas R. Cannell, Chief Operating Officer, Executive Vice President, President - Global Commercial Products
- Thomas P. Lynch, Executive Vice President, General Counsel, Secretary
- Peter Flynn Ph.D., Senior Vice President, Head - Development, Regulatory Affairs and Safety
- Louis C. Bock, Independent Director
- Brian H. Dovey, Independent Director
- David J. Endicott, Independent Director
- Peter K. Honig M.D. M.P.H., Independent Director
Who owns Orexigen Therapeutics stock?
Orexigen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (2.44%), Vanguard Group Inc. (1.71%), Old West Investment Management LLC (1.19%) and Wells Fargo & Company MN (0.30%). View Institutional Ownership Trends for Orexigen Therapeutics.
Who sold Orexigen Therapeutics stock? Who is selling Orexigen Therapeutics stock?
Who bought Orexigen Therapeutics stock? Who is buying Orexigen Therapeutics stock?
How do I buy Orexigen Therapeutics stock?
Shares of Orexigen Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Orexigen Therapeutics' stock price today?
One share of Orexigen Therapeutics stock can currently be purchased for approximately $2.12.
MarketBeat Community Rating for Orexigen Therapeutics (NASDAQ OREX)MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Orexigen Therapeutics (NASDAQ:OREX)Earnings History by Quarter for Orexigen Therapeutics (NASDAQ OREX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($2.13) | | | | | N/A |  |
| 8/8/2017 | Q2 2017 | ($2.40) | ($1.82) | $20.00 million | $23.36 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($2.60) | ($4.67) | $20.00 million | $19.10 million | View | Listen | |
| 11/3/2016 | Q316 | ($2.24) | $1.12 | $8.17 million | $7.00 million | View | N/A | |
| 8/4/2016 | Q216 | ($1.47) | ($1.73) | $6.88 million | $7.79 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.17) | ($0.15) | $7.78 million | $5.00 million | View | Listen | |
| 2/26/2016 | Q415 | ($0.08) | ($0.12) | $14.07 million | $4.90 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.16) | ($0.09) | $12.17 million | $10.00 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.17) | ($0.18) | $4.92 million | $5.20 million | View | Listen | |
| 5/8/2015 | Q115 | ($0.16) | ($0.14) | $7.28 million | $4.36 million | View | Listen | |
| 11/10/2014 | Q3 | ($0.13) | $0.09 | $8.93 million | $30.90 million | View | Listen | |
| 8/7/2014 | Q2 | ($0.21) | ($0.21) | $51.80 million | $0.86 million | View | Listen | |
| 5/8/2014 | Q1 | ($0.20) | ($0.23) | $0.93 million | $0.86 million | View | Listen | |
| 3/12/2014 | Q4 | ($0.19) | ($0.21) | $900.00 million | $857.00 million | View | Listen | |
| 11/12/2013 | Q3 | ($0.18) | ($0.19) | $0.80 million | $0.86 million | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.19) | ($0.19) | $0.90 million | | View | Listen | |
| 3/13/2013 | Q4 2012 | ($0.44) | ($0.41) | $0.91 million | $0.86 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.30) | ($0.44) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)Current Year EPS Consensus Estimate: $-9.37 EPS
Next Year EPS Consensus Estimate: $-5.59 EPS
Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Orexigen Therapeutics (NASDAQ:OREX)Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 39.66%
Insider Trades by Quarter for Orexigen Therapeutics (NASDAQ:OREX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/19/2016 | Stephen A. Moglia | VP | Sell | 800 | $1.96 | $1,568.00 | |
| 12/2/2014 | Heather D Turner | SVP | Sell | 22,643 | $6.00 | $135,858.00 | |
| 11/25/2014 | Heather D Turner | SVP | Sell | 31,388 | $5.83 | $182,992.04 | |
| 11/18/2014 | Louis C Bock | Director | Buy | 1,325 | $5.58 | $7,393.50 | |
| 11/12/2014 | Louis C Bock | Director | Buy | 27,052 | $5.57 | $150,679.64 | |
| 9/22/2014 | Heather D Turner | VP | Sell | 300,000 | $4.47 | $1,341,000.00 | |
| 9/15/2014 | Joseph P Hagan | VP | Buy | 5,000 | $4.69 | $23,450.00 | |
| 9/15/2014 | Michael Narachi | CEO | Buy | 50,000 | $4.78 | $239,000.00 | |
| 7/31/2013 | Joseph P Hagan | Insider | Sell | 12,000 | $7.80 | $93,600.00 | |
| 7/26/2013 | Joseph P Hagan | Insider | Sell | 10,000 | $7.40 | $74,000.00 | |
| 7/25/2013 | Preston Klassen | SVP | Sell | 71,229 | $7.16 | $509,999.64 | |
| 5/28/2013 | Joseph P Hagan | Insider | Sell | 28,000 | $7.00 | $196,000.00 | |
| 5/28/2013 | Preston Klassen | SVP | Sell | 28,771 | $7.21 | $207,438.91 | |
| 1/15/2013 | Mark D Booth | Insider | Sell | 22,315 | $6.67 | $148,841.05 | |
(Data available from 1/1/2013 forward)
Headline Trends for Orexigen Therapeutics (NASDAQ:OREX)
Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)
| Source: |
|
| Date | Headline |
|---|
 | Orexigen Therapeutics to Provide Business Update at the 2017 ... - PR Newswire (press release)
www.prnewswire.com - September 14 at 8:50 AM |
 | Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 14 at 8:50 AM |
| The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
finance.yahoo.com - September 12 at 8:18 AM |
 | Orexigen Therapeutics (OREX) versus CLEMENTIA PHARM (CMTA) Critical Contrast
www.americanbankingnews.com - September 10 at 4:12 AM |
 | Orexigen Therapeutics (OREX) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 9 at 7:05 AM |
| ETFs with exposure to Orexigen Therapeutics, Inc. : September 7, 2017
finance.yahoo.com - September 8 at 6:51 AM |
| Zacks: Analysts Expect Orexigen Therapeutics, Inc. (OREX) to Post -$2.13 Earnings Per Share
www.americanbankingnews.com - September 6 at 6:18 AM |
| Orexigen Therapeutics, Inc. (OREX) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - September 2 at 6:56 PM |
| Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 8:04 AM |
| Zacks Investment Research Upgrades Orexigen Therapeutics, Inc. (NASDAQ:OREX) to Buy
www.americanbankingnews.com - August 14 at 2:30 PM |
| Orexigen Therapeutics, Inc. (OREX) Issues Earnings Results
www.americanbankingnews.com - August 9 at 5:22 PM |
| Orexigen Therapeutics, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 9 at 6:08 AM |
| Orexigen Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 6:08 AM |
| Orexigen reports 2Q loss
finance.yahoo.com - August 9 at 6:08 AM |
| Edited Transcript of OREX earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 6:08 AM |
| Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel ... - PR Newswire (press release)
www.prnewswire.com - August 7 at 8:13 AM |
| Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria
finance.yahoo.com - August 7 at 8:13 AM |
| -$2.40 EPS Expected for Orexigen Therapeutics, Inc. (NASDAQ:OREX) This Quarter
www.americanbankingnews.com - July 31 at 12:28 PM |
| Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave ... - PR Newswire (press release)
www.prnewswire.com - July 28 at 6:33 AM |
| Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt
finance.yahoo.com - July 27 at 6:05 AM |
| Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - July 26 at 6:08 AM |
 | 15 Biggest Mid-Day Gainers For Thursday | Benzinga - Benzinga
www.benzinga.com - July 21 at 5:49 AM |
| Vivus Settlement Could Clue In Orexigen Investors - Seeking Alpha
seekingalpha.com - July 21 at 5:49 AM |
| Martin Shkreli made gay investor uncomfortable with sex talk
finance.yahoo.com - July 19 at 1:08 AM |
| Quintiles IMS: A Novel Way To Invest In Biopharma
seekingalpha.com - July 18 at 7:05 AM |
| A Martin Shkreli hedge fund account had 'negative 33 cents' in it when he claimed millions in assets
finance.yahoo.com - July 12 at 6:43 AM |
| Orexigen Therapeutics, Inc. (NASDAQ:OREX) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 3:38 PM |
| Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction
finance.yahoo.com - July 11 at 6:26 AM |
| Orexigen Therapeutics, Inc. (OREX) Expected to Post Earnings of -$2.40 Per Share
www.americanbankingnews.com - July 7 at 8:54 AM |
 | Pricing, Competition Remain Headwinds for Pharma in 2017 - Nasdaq
www.nasdaq.com - June 30 at 3:00 AM |
| Orexigen (OREX) Down 9.4% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - June 16 at 8:35 AM |
| Edison Issues Outlook on Orexigen Therapeutics (OREX)
finance.yahoo.com - June 16 at 8:35 AM |
| Orexigen (OREX) Down 9.4% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 14 at 9:02 AM |
| -$2.40 EPS Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter
www.americanbankingnews.com - June 13 at 8:18 AM |
| Cumberland Pharmaceuticals (CPIX) vs. Orexigen Therapeutics (OREX) Financial Comparison
www.americanbankingnews.com - June 10 at 7:38 AM |
| ETFs with exposure to Orexigen Therapeutics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 7:40 PM |
| Summit Therapeutics PLC (SMMT) and Orexigen Therapeutics (OREX) Head to Head Review
www.americanbankingnews.com - June 4 at 6:12 PM |
| Orexigen Therapeutics, Inc. (OREX) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - June 3 at 6:58 PM |
| Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 9:18 PM |
| Orexigen Therapeutics (OREX) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 22 at 6:16 PM |
| Orexigen Announces Activities at European Congress on Obesity 2017
finance.yahoo.com - May 16 at 6:47 PM |
| -$2.40 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter
www.americanbankingnews.com - May 16 at 4:04 PM |
| Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 - PR Newswire (press release)
www.prnewswire.com - May 11 at 7:32 PM |
| Edited Transcript of OREX earnings conference call or presentation 9-May-17 9:00pm GMT
finance.yahoo.com - May 11 at 12:18 AM |
| Orexigen Therapeutics, Inc. (OREX) Announces Quarterly Earnings Results, Misses Expectations By $2.07 EPS
www.americanbankingnews.com - May 10 at 7:40 PM |
| Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y
finance.yahoo.com - May 10 at 11:49 AM |
 | BRIEF-Orexigen Therapeutics reports Q1 loss per share $4.67
www.reuters.com - May 9 at 6:40 PM |
| Orexigen Therapeutics, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 9 at 6:40 PM |
| Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 6:40 PM |
| Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017
finance.yahoo.com - May 9 at 6:40 PM |
Orexigen Therapeutics (OREX) Chart for Sunday, September, 24, 2017
